Search | OpenScholar

Search results

755 results found

Hauser RA. How to dose carbidopa and levodopa extended release capsules (Rytary). Clinical Medicine Journal 2015;1:34-7.

Publication: Journal Article

“Hauser RA. How to Dose Carbidopa and Levodopa Extended Release Capsules (Rytary). Clinical Medicine Journal 2015;1:34-7.”. 2015. Clinical Medicine Journal.

Amantadine extended release for levodopa-induced dyskinesia in Parkinson's disease (EASED Study). Mov Disord 2015;30:788-95.

Publication: Journal Article

Pahwa, R, CM Tanner, RA Hauser, K Sethi, S Isaacson, D Truong, L Struck, et al. 2015. “Amantadine Extended Release for Levodopa-Induced Dyskinesia in Parkinson’s Disease (EASED Study). Mov Disord 2015;30:788-95.”. Mov Disord.

NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: A randomized, double-blind, placebo-controlled study. Mov Disord 2015;30:1681-7.

Publication: Journal Article

O’Brien, CF, R Jimenez, RA Hauser, SA Factor, J Burke, D Mandri, and JC Castro-Gayol. 2015. “NBI-98854, a Selective Monoamine Transport Inhibitor for the Treatment of Tardive Dyskinesia: A Randomized, Double-Blind, Placebo-Controlled Study. Mov Disord 2015;30:1681-7.”. Mov Disord.

Neurogenic orthostatic hypotension and supine hypertension in Parkinson's disease and related synucleinopathies: prioritisation of treatment targets. Lancet Neurol 2016;15:954-66.

Publication: Journal Article

Espay, AJ, PA LeWitt, RA Hauser, A Merola, M Masellis, and AE Lang. 2016. “Neurogenic Orthostatic Hypotension and Supine Hypertension in Parkinson’s Disease and Related Synucleinopathies: Prioritisation of Treatment Targets. Lancet Neurol 2016;15:954-66.”. Lancet Neurol.

Long-term effects of rasagiline and the natural history of treated Parkinson's disease. Mov Disord 2016;31:1489-1496.

Publication: Journal Article

Rascol, O, RA Hauser, F Stocchi, CJ Fitzer-Attas, Y Sidi, V Abler, CW Olanow, and AFU Investigators. 2016. “Long-Term Effects of Rasagiline and the Natural History of Treated Parkinson’s Disease. Mov Disord 2016;31:1489-1496.”. Mov Disord.

Effects of Gocovri (Amantadine) Extended-Release Capsules on Motor Aspects of Experiences of Daily Living in People with Parkinson's Disease and Dyskinesia. Neurol Ther. 2021 Dec;10(2):739-751. doi: 10.1007/s40120-021-00256-1.

Publication: Journal Article

Hauser, RA, SH Mehta, D Kremens, D Chernick, and AE Formella. 2021. “Effects of Gocovri (Amantadine) Extended-Release Capsules on Motor Aspects of Experiences of Daily Living in People With Parkinson’s Disease and Dyskinesia. Neurol Ther. 2021 Dec;10(2):739-751. Doi: 10.1007/S40120-021-00256-1.”. Neurol Ther.

Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3). Mov Disord 2017;32:1701-1709.

Publication: Journal Article

Oertel, W, K Eggert, R Pahwa, CM Tanner, RA Hauser, C Trenkwalder, R Ehret, et al. 2017. “Randomized, Placebo-Controlled Trial of ADS-5102 (amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson’s Disease (EASE LID 3). Mov Disord 2017;32:1701-1709.”. Mov Disord.

CD 140 Study Group. Efficacy, tolerability, and immunogenicity of onabotulinumtoxina in a randomized, double-blind, placebo-controlled trial for cervical dystonia. Clin Neuropharmacol 2012;35:208-14.

Publication: Journal Article

Charles, D, A Brashear, RA Hauser, Li HI, LM Boo, and MF Brin. 2012. “CD 140 Study Group. Efficacy, Tolerability, and Immunogenicity of Onabotulinumtoxina in a Randomized, Double-Blind, Placebo-Controlled Trial for Cervical Dystonia. Clin Neuropharmacol 2012;35:208-14.”. Clin Neuropharmacol.

Randomized clinical trial of fipamezole for dyskinesia in Parkinson disease (FJORD study). Neurology 2012;79:163-9.

Publication: Journal Article

LeWitt, PA, RA Hauser, M Lu, AP Nicholas, W Weiner, N Coppard, M Leinonen, and JM Savola. 2012. “Randomized Clinical Trial of Fipamezole for Dyskinesia in Parkinson Disease (FJORD Study). Neurology 2012;79:163-9.”. Neurology.

A(2A) Receptor Antagonism and Dyskinesia in Parkinson's Disease. Parkinsons Dis 2012;1-8.

Publication: Journal Article

Morelli, M, F Blandini, N Simola, and RA Hauser. 2012. “A(2A) Receptor Antagonism and Dyskinesia in Parkinson’s Disease. Parkinsons Dis 2012;1-8.”. Parkinsons Dis.